Two studies show the new antibiotic is safe and effective for difficult-to-treat MDR infections.
One more Ebola case has been confirmed in the Democratic Republic of the Congo (DRC) Equateur province outbreak, raising the total to 68 cases, the World Health Organization (WHO) African regional office said today on Twitter.
The patient is apparently from Mbandaka, the provincial capital, which is a concern, given its travel connections to Kinshasa and neighboring countries. The number of deaths held steady at 31.
A study of children hospitalized for community-acquired pneumonia (CAP) found that a shorter course of antibiotics did not increase the odds of treatment failure compared with a longer course, US researchers reported today in the Journal of the Pediatric Infectious Diseases Society.
The study provides clear evidence of the power of childhood vaccines on reducing the antibiotic resistance burden.
Data on children treated for mild pneumonia suggests antibiotics may not be needed as often as prescribed.
The findings question the "more is better" mantra for preventing MRSA.
CARB-X said today it has awarded Lytica Therapeutics, of Cambridge, Massachusetts, up to $5.3 million to develop antibacterial peptides that have broad activity against multidrug-resistant bacteria for treating lung and other infections.
All three confirmed Ebola cases reported in the past week in the Democratic Republic of the Congo (DRC) involved known transmission chains, which is a good sign, but volatile situations still plague the outbreak region, the World Health Organization (WHO) said yesterday in its weekly situation report.
Hong Kong, meanwhile, reports a respirator shortage.
The CDC issues a watch but does not call for travel limits.
